Keros Therapeutics Inc
KROS
Get informed when a big investor buys or sells
+ FollowMarket Cap$340.46M
Close$
$13.60
35.1% upside
Current Fair Value
35.1% upsideUndervalued by 35.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $340.46 Million |
|---|---|
| Enterprise Value | $75.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.34 |
| Beta | 0.97 |
| Outstanding Shares | 37,221,211 |
Return
| Return on Equity | -29.81% |
|---|---|
| Return on Assets | -27.26% |
| Return on Invested Capital | -40.62% |
Valuation & Multiples
| P/E Ratio | -4.36 |
|---|---|
| PEG | 3.76 |
| Price to Sales | - |
| Price to Book Ratio | 1.44 |
| Enterprise Value to Revenue | 2.27 |
| Enterprise Value to EBIT | -0.62 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.92
Average shareholder expectationRevenue Estimate
$1.93 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-1.25
Average shareholder expectationRevenue Estimate
$807,143
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.3198▲ 188.20% |
|---|---|
| Total Calls | 88,500▼ 81.81% |
| Total Puts | 205,300▼ 3.62% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 49.96%▼ 4.14% |
|---|---|
| Total Invested | $205.56M▼ 49.88% |
| Investors Holding | 156▼ 16.00% |
ESG Score
No data